Clinical Trial Update: A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a single infusion of VAY736 in relapsing-remitting multiple sclerosis; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapse Remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2019-10-30